Abstract
Allergan is a global specialty pharmaceutical company that develops and
commercializes products for the eye care, neuromodulator, skin care and other
specialty markets. This report provides a full review of the company' s
activities together with sales forecasts for key products to 2010.
With headquarters in Irvine, California, Allergan is a global specialty
pharmaceutical company that develops and commercializes products for the eye
care, neuromodulator, skin care and other specialty markets. In addition to
its discovery-to-development research programmes, Allergan, which was founded
in 1948, has global marketing and sales capabilities in over 100 countries. It
has a workforce of over 5,000 people and invests approximately US$390 million
per year in research and development.
Over recent years, Allergan has made a number of changes aimed at simplifying
the company' s business model, enabling Allergan to take advantage of its
position as a relatively modest player in the pharmaceutical industry.
Allergan has chosen a distinct company strategy, focusing strongly on the
development and marketing of speciality products. This tactic seems to have
proved effective, with Allergan achieving a market leader position in the area
of neuromodulators with Botox, and in ophthalmology with its range of eye care
therapeutics. The recent acquisition of Inamed should ensure Allergan
maintains a strong presence in the field of medical aesthetics as well.
Historically, Allergan' s expertise has been in the development of topical
pharmaceuticals for ophthalmology and dermatology. In recent years, the
company has begun building new competencies in the design and clinical
investigation of oral drugs. Allergan is aiming to build a balanced pipeline
of innovative new chemical entities, line extensions and product enhancements
that deliver a consistent flow of new products to drive corporate growth.
Allergan is focusing its R&D efforts on new therapeutic areas, including
gastroenterology and genitourinary diseases. Allergan is also focusing on the
more severe end of the spectrum of the dermatological diseases of acne and
psoriasis.
View Cart
